ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer.

J Clin Oncol · 2021 · PMC7771720 · PMID 33052757

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

22 Patient inclusion in the ARTSCAN III study was prematurely terminated, and the primary end point OS did not reach statistical significance between the treatment groups in this first analysis of the study.

also in 111,027 other papers

highly significantno p-value reported

In contrast, event-free survival, known to be strongly correlated with OS, 23 was highly significant in favor of cisplatin treatment.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.